CompaniesGema Biotech

Gema Biotech

defunct
About

Defunct Company

Areas of Focus

Categories

Terminally AcquiredBankrupt, Merged, Sold, Renamed or Otherwise Defunct
Clinical Trials (4)
View all

Total Trials

4

As Lead Sponsor

4

As Collaborator

0

Total Enrollment

535

By Phase

PHASE3: 4

By Status

UNKNOWN: 2COMPLETED: 2
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2014
2015
2016
2017
2018
2019
Today
NCT02454556
NCT03404752
NCT03332719
NCT03403140
Hover over trial bars to see details

Recent Trials

NCT03403140Lead Sponsor
Long Term Efficacy, Safety and Immunogenicity of Enerceptan in Rheumatoid Arthritis ( GEMENE002 )
PHASE3Unknown
141 participants
Started: Oct 6, 2016 · Completed: Oct 31, 2018
NCT03332719Lead Sponsor
Efficacy, Safety and Immunogenicity of Enerceptan Compared to Enbrel in Rheumatoid Arthritis
PHASE3Completed
168 participants
Started: Feb 29, 2016 · Completed: Sep 30, 2017
NCT03404752Lead Sponsor
Pegfilgrastim-gema Compared to Pegfilgrastim-roche for Prevention of Induced Neutropenia in Breast Cancer Patients.
PHASE3Unknown
120 participants
Started: Aug 31, 2015 · Completed: Dec 31, 2018
NCT02454556Lead Sponsor
A Randomized, Multicentre, Open Label, Evaluator Blinded Study to Evaluate Safety and Efficacy of Folitime® of Gemabiotech S.A., Versus Gonal-f ® of Merck Serono, in Patients With Infertility Undergoing ART
PHASE3Completed
106 participants
Started: Apr 30, 2015 · Completed: Dec 31, 2016
Related Companies
Amega Biotech
acquired